Dr. Gage joins the Cytokinetics Board of Directors with over 35 years of experience in the discovery and development of high-impact pharmaceuticals. Since July 2002, he has served as a consultant to the biopharmaceutical industry, including service as an advisor to venture capital firms. From 1998 to 2002, Dr. Gage was President of Wyeth Research and subsequently also Senior Vice President, Science and Technology. From 1989 to 1998, he held roles of increasing responsibility at Genetics Institute, Inc., one of the pioneers in the biotechnology industry, first as head of Research and Development then Chief Operating Officer and eventually as President. From 1971 to 1989, Dr Gage held various positions in research management with Hoffmann-La Roche Inc. most recently serving as Vice President responsible for US drug discovery. During his career at Wyeth, Genetics Institute and Roche, he was involved in the discovery and development of more than a dozen novel marketed biologics, as well as many small molecule drugs.

Dr. Gage currently serves as Executive Chairman of Virdante Pharmaceuticals, and is also a Director of Acceleron Pharma, Alvine Pharmaceuticals and Immune Control, which are all privately held companies. In the past, he served as Chairman and also as Interim CEO of PDL BioPharma, Chairman of Neose Technologies, Chairman of Adnexus Therapeutics, now a unit of Bristol Myers Squibb Research, and as a Director of ArQule, Inc. and Serono, which was acquired by Merck KGA. Dr. Gage earned his bachelor's degree in Physics from the Massachusetts Institute of Technology and his Ph.D. in Biophysics from the University of Chicago.

"We are pleased to welcome Pat to our Board of Directors at this important next stage of Cytokinetics' evolution," stated Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "As a highly respected and seasoned R&D executive with valuable pharmaceutical and biotechnology industry experience, we look forward to Pat's expert engagement and assistance in guiding our objectives to bring breakthrough medicines towards potential registration and commercialization."

"I am excited about joining the Cytokinetics' Board," stated Dr. Gage.